Cara Therapeutics Inc. (TVRD)
NASDAQ (CM) 
Summary
TVRD Chart
Cara Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 15 | $365.59 | $47.62 | -$317.97 | -86.97% |
 Farallon Capital Farallon Capital Management LLC | 21,438 | $500,148.42 | $68,387.22 | -$431,761.2 | -86.33% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 1 | $3.18 | $3.03 | -$0.15 | -4.72% |
 Kevin Kroskey True Wealth Design LLC | 9 | $29 | $26.37 | -$2.63 | -9.07% |
| WPA Wealth Preservation Advisors LLC Wealth Preservation Advisors LLC | 8 | $25 | $25.52 | $0.52 | 2.08% |
Cara Therapeutics Inc. (TVRD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cara Therapeutics Inc. ever had a stock split?
Cara Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher A. Posner CEO | NASDAQ (CM) Exchange | 140755307 CUSIP |
| US Country | 10 Employees | - Last Dividend | 2 Jan 2025 Last Split | 31 Jan 2014 IPO Date |
Overview
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company with a primary focus on creating and bringing to market treatments for chronic pruritus. Established in 2004 and situated in Stamford, Connecticut, the company has made significant strides in developing therapeutics that address the unmet medical needs of patients suffering from persistent itching associated with various conditions. Cara Therapeutics has established critical partnerships with leading pharmaceutical companies across the globe, such as Maruishi Pharmaceutical Co., Ltd in Japan, Vifor Fresenius Medical Care Renal Pharma Ltd., and Chong Kun Dang Pharmaceutical Corporation in South Korea, to expand the development, manufacturing, and commercialization of its lead product, KORSUVA (difelikefalin), and its variations for different indications.
Products and Services
- KORSUVA (difelikefalin) Injection
This is Cara Therapeutics' flagship product, developed for the treatment of moderate-to-severe pruritus in adults undergoing hemodialysis due to chronic kidney disease (CKD). By specifically targeting the underlying causes of itch in CKD patients, KORSUVA injection offers a novel approach to managing this debilitating symptom, which is widely prevalent yet underserved in the current therapeutic landscape.
- Oral Difelikefalin
In addition to its intravenous formulation, Cara Therapeutics is also developing an oral version of difelikefalin. This formulation is currently undergoing Phase II/III clinical trials, aiming to offer a treatment solution for chronic pruritus associated with notalgia paresthetica. The success of this formulation could significantly expand the company's market reach, providing patients suffering from pruritus of various etiologies with a much-needed oral medication option.
